Creative Medical Technology (CELZ) said Friday that it received a notice of allowance from the US Patent and Trademark Office for ImmCelz for the treatment of heart failure and post-infarct pathological remodeling.

Once granted, the patent will be in effect until at least 2040, the biotechnology company said.

The patent has broad claims on using ImmCelz via a minimally invasive outpatient procedure to treat patients at risk of developing or who already have heart failure, the company said.

Shares of the company were up 4.5% in recent premarket activity.